Paterna S, Di Pasquale P, Parrinello G, Amato P, Bucca V, Cecala M, Cardinale A, Maniscalchi T, Tuttolomondo A, Bova A, Arrostuto A, Follone G, Bologna P, Piovana G, Licata G
Department of Internal Medicine, University of Palermo, Italy.
Drugs Exp Clin Res. 1998;24(3):159-63.
Recent reports show that sumatriptan administration increases blood pressure and vascular resistance both in systemic and pulmonary circulation. This study was performed to evaluate by echo-Doppler technique the hemodynamic effects of subcutaneous sumatriptan administration. Forty-one migraine subjects (26 males, 15 females), mean age 36 +/- 2 years (range 36-39 years), and 20 healthy control subjects (14 males, six females), mean age 36 +/- 2 years (range 36-39 years) were randomized (double-blind) to receiving sumatriptan (group A) or placebo (group B). After a 2-week complete pharmacological washout, clinical examination, electrocardiogram, and Doppler echocardiography were performed at baseline, 15, 30, 45, and 60 min after sumatriptan or placebo administration. No significant differences were found between the two groups regarding Doppler echocardiographic parameters (aortic integral, pulmonary integral, end-systolic and end-diastolic diameters) and heart rate; only a slight but not significant increase in arterial blood pressure was observed in group A. Our data show that succinate sumatriptan can be used with safety in patients without hypertension and other cardiovascular disease.
最近的报告显示，舒马曲坦给药会增加体循环和肺循环中的血压和血管阻力。本研究旨在通过超声多普勒技术评估皮下注射舒马曲坦的血流动力学效应。41名偏头痛患者（26名男性，15名女性），平均年龄36±2岁（范围36 - 39岁），以及20名健康对照者（14名男性，6名女性），平均年龄36±2岁（范围36 - 39岁），被随机（双盲）分为接受舒马曲坦组（A组）或安慰剂组（B组）。经过2周的完全药物洗脱期后，在给予舒马曲坦或安慰剂后的基线、15、30、45和60分钟进行临床检查、心电图和多普勒超声心动图检查。两组在多普勒超声心动图参数（主动脉积分、肺动脉积分、收缩末期和舒张末期直径）和心率方面未发现显著差异；仅在A组观察到动脉血压有轻微但不显著的升高。我们的数据表明，琥珀酸舒马曲坦可安全用于无高血压和其他心血管疾病的患者。
